Analysts Offer Insights on Healthcare Companies: Tyme Technologies Inc (TYME) and MannKind (MNKD)


There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Tyme Technologies Inc (TYME) and MannKind (MNKD) with bullish sentiments.

Tyme Technologies Inc (TYME)

In a report released today, Swayampakula Ramakanth from H.C. Wainwright initiated coverage with a Buy rating on Tyme Technologies Inc and a price target of $9.50. The company’s shares closed on Friday at $0.98, close to its 52-week low of $0.92.

Ramakanth observed:

“We maintain our Buy rating of TYME and our 12-month price target of $9.50 per share. We derive our price target based on a net present value analysis of projected SM-88 revenues through FY2030, assuming a 12% discount rate and 2% terminal growth rate.”

According to TipRanks.com, Ramakanth ‘s ranking currently consits of no stars on a 0-5 ranking scale, with an average return of -11.9% and a 28.2% success rate. Ramakanth covers the Healthcare sector, focusing on stocks such as Zomedica Pharmaceuticals Corp, IntelGenx Technologies, and Gritstone Oncology Inc.

The word on The Street in general, suggests a Moderate Buy analyst consensus rating for Tyme Technologies Inc with a $9.50 average price target.

See today’s analyst top recommended stocks >>

MannKind (MNKD)

H.C. Wainwright analyst Oren Livnat reiterated a Buy rating on MannKind today and set a price target of $3. The company’s shares closed on Friday at $1.08, close to its 52-week low of $0.94.

Livnat commented:

“Our $3 target is based on a DCF reflecting only U.S. Afrezza sales, assuming acceleration in 2021 and beyond, and peak potential of approximately $300M. We apply a 11% WACC discount rate, and 2.5% terminal growth beyond 2026 (equating to an 9x terminal EBITDA multiple). We think robust terminal growth is justified given the broadly applicable inhalable formulation technology platform, potential ex-U.S.”

According to TipRanks.com, Livnat is a 4-star analyst with an average return of 6.7% and a 51.4% success rate. Livnat covers the Healthcare sector, focusing on stocks such as Verrica Pharmaceuticals Inc, Taiwan Liposome Company Ltd, and Collegium Pharmaceutical.

Currently, the analyst consensus on MannKind is a Moderate Buy with an average price target of $3.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

Stay Ahead of Everyone Else

Get The Latest Stock News Alerts